Business Context and Reporting Period
This Form 10-Q covers Gilead Sciences, Inc. for the three-month period ended March 31, 1999. Gilead is a biopharmaceutical company focused on the discovery, development, and commercialization of products for serious illnesses. Its primary marketed product is VISTIDE (cidofovir) for CMV retinitis in AIDS patients. The company is currently in a pre-profitability stage, relying on product sales, royalties, and contract research revenue to fund significant R&D programs.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Total Revenues | $4.9 million | $13.6 million |
| Net Loss | $(15.8) million | $(7.4) million |
| Loss Per Share (Basic/Diluted) | $(0.51) | $(0.25) |
| Net Cash Used in Operating Activities | $(17.3) million | $(6.8) million |
| Cash and Cash Equivalents (End of Period) | $58.4 million | $34.3 million |
| Short-term Investments | $205.5 million | $N/A (Not explicitly stated for Q1 1998 end) |
| Total Liquid Assets (Cash + Short-term) | $263.9 million | $N/A |
| Accumulated Deficit | $(234.3) million | $(218.6) million |
| Long-term Debt | $1.1 million | $N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues dropped 64% to $4.9 million from $13.6 million. This was driven primarily by a decrease in contract revenue from $11.4 million to $2.9 million due to a reduced role in the development of GS 4104 (oseltamivir) with Roche. Product sales also declined slightly due to improved HIV therapies reducing the incidence of CMV retinitis.
- Increased Net Loss: Net loss more than doubled to $15.8 million from $7.4 million. While R&D expenses decreased by $3.1 million (due to the Roche project shift), SG&A expenses increased by $1.6 million (24%) to support the anticipated launch of PREVEON.
- Liquidity Position: Despite operating cash burn, total cash and short-term investments increased to $263.9 million from $279.9 million at year-end 1998, aided by net cash provided by investing activities ($38.8 million) and financing activities ($4.5 million).
Outlook, Risks, and Unusual Items
- Merger Activity: On March 1, 1999, Gilead announced a definitive merger agreement to acquire NeXstar Pharmaceuticals, Inc. in a tax-free, stock-for-stock transaction expected to close in mid-1999.
- Future Expenses: Management expects R&D and SG&A expenses to increase significantly throughout 1999 to support clinical trials for multiple product candidates and the potential launch of PREVEON.
- Revenue Outlook: VISTIDE sales are expected to remain comparable to 1998 levels or decline further. Contract revenue from Roche is expected to be significantly lower for the remainder of 1999.
- Year 2000 Compliance: The company is implementing a Y2K project with estimated external costs of $2.0 million. Management believes the cost will not be material to financial condition, though risks remain regarding third-party supplier compliance.
- Risks: Significant risks include the uncertainty of clinical trial outcomes, regulatory approvals, the success of the NeXstar merger, and the potential for continued losses.
Investor Verification Checklist
- Verify the status and expected closing date of the NeXstar Pharmaceuticals merger.
- Confirm the timeline and budget for the launch of PREVEON and other pipeline candidates.
- Monitor the progress of Year 2000 compliance for critical third-party suppliers and internal systems.
- Review the specific milestones required to unlock the remaining $32.0 million in potential payments from Roche.
- Assess the sustainability of the current cash burn rate against the $263.9 million liquidity position.